Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells.
Rhabdomyosarcoma is a soft tissue tumor committed to the myogenic lineage but arrested prior to terminal differentiation. To identify new genes implicated in the block in myogenic differentiation of rhabdomyosarcoma cells and those responsible for their proceeding along the myogenic pathway we used cDNA microarrays to compare gene expression profiles of two clones of the human embryonal rhabdomyosarcoma cell line RD with different myogenic potentials: RD/12, which is unable to differentiate, and RD/18, which shows elements able to terminally differentiate, as defined by the expression of myosin heavy chain (up to 50% of the population) and the formation of multinucleated myotube-like structures. We identified 80 genes differentially expressed by the two clones. Differentiating RD/18 cells overexpressed the myogenic transcription factor myogenin along with known myogenic markers; myogenin transfection into undifferentiated RD/12 cells was able to revert the phenotype giving rise to 94% of clones displaying a differentiated morphology. RD/18 cells also expressed several genes not known to be expressed in rhabdomyosarcoma or muscle cells, such as pigment-epithelium derived factor and endothelin-3. Poorly differentiated RD/12 cells, along with genes related to mesenchymal lineage or early myogenic commitment, also expressed genes not previously known to be related to the differentiation block of human rhabdomyosarcoma, such as monocyte chemotactic protein-1, connective tissue growth factor and insulin-like growth factor binding protein-5. Differential expression of these genes in a time course of differentiation suggested their potential roles as either new myogenic markers or repressors of differentiation. These results identify a cluster of new genes related to the aberrant myogenic differentiation program of human rhabdomyosarcoma cells.
Astolfi
A
A
Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Bologna, Italy
De Giovanni
C
C
Landuzzi
L
L
Nicoletti
G
G
Ricci
C
C
Croci
S
S
Scopece
L
L
Nanni
P
P
Lollini
P L
PL
D002454:Cell Differentiation / Q000235:genetics*; D018932:Chemokine CCL2 / Q000235:genetics; D055513:Connective Tissue Growth Factor; D004305:Dose-Response Relationship, Drug; D019334:Endothelin-3 / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006133:Growth Substances / Q000235:genetics; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000235:genetics / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins; D009132:Muscles / Q000166:cytology / Q000378:metabolism*; D018008:Myogenin / Q000235:genetics; D009218:Myosins / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D012208:Rhabdomyosarcoma / Q000235:genetics* / Q000473:pathology; D013997:Time Factors; D014407:Tumor Cells, Cultured
C526317:CCN2 protein, human; D018932:Chemokine CCL2; D019334:Endothelin-3; D006133:Growth Substances; D017874:Immediate-Early Proteins; D018975:Insulin-Like Growth Factor Binding Protein 5; D036341:Intercellular Signaling Peptides and Proteins; C503799:MYOG protein, human; D018008:Myogenin; D055513:Connective Tissue Growth Factor; D009218:Myosins